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Background: Recently, it has been shown that carnitine down-regulates genes involved in the ubiquitin-proteasome
system (UPS) in muscle of pigs and rats. The mechanisms underlying this observation are yet unknown. Based on the
previous finding that carnitine increases plasma IGF-1 concentration, we investigated the hypothesis that carnitine
down-regulates genes of the UPS by modulation of the of the IGF-1/PI3K/Akt signalling pathway which is an important
regulator of UPS activity in muscle.
Methods: Male Sprague–Dawley rats, aged four weeks, were fed either a control diet with a low native carnitine
concentration or the same diet supplemented with carnitine (1250 mg/kg diet) for four weeks. Components of the UPS
and IGF-1/PI3K/Akt signalling pathway in skeletal muscle were examined.
Results: Rats fed the diet supplemented with carnitine had lower mRNA and protein levels of MuRF1, the most
important E3 ubiquitin ligase in muscle, decreased concentrations of ubiquitin-protein conjugates in skeletal muscle and
higher IGF-1 concentration in plasma than control rats (P < 0.05). Moreover, in skeletal muscle of rats fed the diet
supplemented with carnitine there was an activation of the PI3K/Akt signalling pathway, as indicated by increased
protein levels of phosphorylated (activated) Akt1 (P < 0.05).
Conclusion: The present study shows that supplementation of carnitine markedly decreases the expression of MuRF1
and concentrations of ubiquitinated proteins in skeletal muscle of rats, indicating a diminished degradation of
myofibrillar proteins by the UPS. The study moreover shows that supplementation of carnitine leads to an activation of
the IGF-1/PI3K/Akt signalling pathway which in turn might contribute to the observed down-regulation of MuRF1 and
muscle protein ubiquitination.
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The protein turnover represents a finely regulated bal-
ance between protein synthesis and degradation. Many
regulatory proteins have very short half-time and are
rapidly hydrolyzed to their constituent amino acids and
replaced by newly synthesized proteins. In mammalian
tissues, proteins are degraded mainly by the ubiquitin-
proteasome system (UPS) [1,2]. The UPS is part of all
eukaryotic cells and involves a complex cascade of* Correspondence: Klaus.Eder@ernaehrung.uni-giessen.de
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reproduction in any medium, provided the orenzymes and displays a high degree of specificity to-
wards its numerous substrates [3]. The tagging process,
which involves the linking of ubiquitin chain to proteins
via an isopeptide bond, is the rate limiting process me-
diated by three enzymatic steps. First, ubiquitin is
bound via its carboxyl terminus to the sulfhydryl group
of ubiquitin-activating enzyme (E1). Thereafter, ubiqui-
tin is transferred from E1 to ubiquitin-conjugating en-
zyme (E2), via formation a high energy thioester linkage
[4]. In the last step, the specific ubiquitin-ligase en-
zymes (E3), in skeletal muscle mainly muscle RINGtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ε-amino group of the target protein. Polyubiquitinated
proteins can be recognized by the downstream 26S pro-
teasome, a multicatalytic protease complex, and rapidly
degraded into smaller peptides [5,6]. The expression of
MuRF1 and atrogin-1 is markedly up-regulated during
several catabolic states such as cancer, kidney failure,
burn injury, sepsis, muscle denervation, diabetes and
starvation [7-10]. It was shown that genetic deletion of
MuRF1 and atrogin-1 results in significantly increased
sparing of muscle mass loss induced by muscle denerv-
ation. This clearly demonstrates the important role of
these atrophy-regulated genes as key factors of myofi-
brillar protein breakdown by the ubiquitin-dependent
proteolysis [7].
With regard to the regulation of the UPS pathway, it
was shown that elevated insulin-like growth factor 1
(IGF-1) levels lead to a reduction in the expression of
MuRF1 and atrogin-1 and, thereby, a decreased protein
degradation by the 26S proteasome in skeletal muscle
[11]. Binding of IGF-1 to its receptor induces a conform-
ational change in the IGF-1 receptor tyrosine kinase,
resulting in a multiple auto-phosphorylation cascade.
As a consequence, phosphoinositide-3-kinase (PI3K)
is activated and downstream Akt (also named protein
kinase B) translocates to the membrane, where it be-
comes phosphorylated (at threonine308 and serine473)
and thereby activated by PI3K [12,13]. Activation of
PI3K/Akt in turn leads to phosphorylation and in-
activation of a specific transcription factor family
named forkhead box O transcription factors (FoxOs).
Consequently, the translocation of FoxOs into the
cell nucleus is repressed and the induction of tran-
scription of the skeletal muscle-specific E3 ligases,
atrogin-1 and MuRF1 is not initiated [14].
Recently, it has been shown that supplementation of car-
nitine (3-hydroxy-4-N,N,N-trimethylaminobutyric acid),
an endogenous compound best known for its function in
the transport of long-chain fatty acids into the mito-
chondrion, leads to a down regulation of genes involved
in the UPS in skeletal muscle of growing pigs [15].
More recently, it has been found that carnitine even in-
hibits proteasomal protein degradation and reduces
muscle wasting in a rat model of cancer cachexia [16].
Thus, carnitine could be a promising compound to sup-
press muscle wasting under catabolic conditions. How-
ever, the mechanism underlying the effect of carnitine
on the expression of genes of the UPS is yet unknown.
In myotubes, used as a model of skeletal muscle cells,
incubation with carnitine did not influence the expres-
sion of genes of the UPS, suggesting that carnitine has
no direct but rather indirect effects on the UPS in
muscle cells [15]. Studies in animals and humans have
shown that supplementation of carnitine increases plasmaconcentrations of IGF-1 [17-19]. Due to the important role
of IGF-1 in the activation of the IGF-1/PI3K/Akt signalling
pathway, we hypothesized that the effect of carnitine on
the UPS in skeletal muscle could be mediated by an activa-
tion of the IGF-1/PI3K/Akt signalling pathway. To investi-
gate this hypothesis, we performed an experiment with
rats, fed either a control diet or a diet supplemented with
carnitine, and considered UPS and the IGF-1/PI3K/Akt
signalling pathway in skeletal muscle.
Methods
Animal experiment
Twenty-four male Sprague–Dawley rats obtained from
Charles River (Sulzfeld, Germany) at four weeks of age
with an average body weight of 111 (± 4 SD) g were
housed in groups of three animals in Macrolon cages in
a room controlled for temperature (22 ± 1°C), relative
humidity (50–60%), and light (12-h-light/-dark cycle).
After seven days of acclimatization, rats were randomly
assigned to two groups (n = 12/group) and individually
housed. A basal diet with a low carnitine concentration
(< 1 mg/kg diet) was formulated. This diet consisted of
(g/kg): Wheat (310), barley (156), corn (150), oats (50),
extracted soybean meal (250), soy oil (30), L-lysine (9),
DL-methionine (5), mineral mixture (30), vitamin mix-
ture (10). Vegetable diet components were used as
sources of protein as they have lower concentrations of
carnitine than protein sources of animal origin. This
diet contained 14.4 MJ metabolizable energy and 194 g
crude protein per kg. Concentrations of amino acids,
minerals and vitamins were in agreement with the re-
quirements for growing rats, according to the AIN-93G
reference [20]. The control group received this diet
without carnitine supplementation, whereas the “car-
nitine group” received the diet supplemented with
1250 mg L-carnitine/kg (obtained from Lohmann
Animal Health, Cuxhaven, Germany). Food and water
was available ad libitum during the whole experi-
ment. The diets were fed for 28 days. All experimen-
tal procedures were in strict accordance with the
recommendations in the guidelines for the care and
use of laboratory animals [21] and the Appendix A
of European Convention for the Protection of Verte-
brate Animals used for Experimental and other Sci-
entific Purposes. In Accordance with Article 4 par. 3
of the German Animal Welfare Law all animals were
humanely killed for scientific purpose approved by the
Animal Welfare Officer of the Justus-Liebig-University,
JLU No. 422_M.
Sample collection
At day 29, rats were killed by decapitation under anesthesia
with carbon dioxide. Blood was collected in heparinized
tubes and plasma was obtained by centrifugation (1,100 g;
Keller et al. Nutrition & Metabolism 2013, 10:28 Page 3 of 12
http://www.nutritionandmetabolism.com/content/10/1/2810 min; 4°C). Liver and skeletal muscle (M. quadriceps
femoris, M. extensor digitorum longus, M. gastrocnemius,
M. soleus) samples were excised. All muscles from both
the left and right limb were weighed and subsequently
snap-frozen in liquid nitrogen. All tissue samples were
stored at −80°C pending further analysis.
Determination of concentrations of protein and
triglycerides in muscles
For determination of the protein concentration, frozen
muscle samples (30 mg) were homogenized in RIPA buf-
fer (radioimmunoprecipitation assay buffer; 50 mM Tris,
150 mM NaCl, 10% glycerol, 0.1% SDS, 1% Triton X-100,
1 mM EDTA, 0.5% deoxycholate, 1% protease inhibitor
mix; pH 7.5) using an Ultraturrax (IKA Werke GmbH,
Staufen, Germany). The homogenate was centrifuged at
16,200 g (4°C) for 15 min. Protein concentrations were
determined in the supernatants using the bicinchoninic
acid protein assay kit (Interchim, Montluçon, France)
with BSA as standard.
Lipids from muscles were extracted with a mixture of
n-hexane and isopropanol (3:2, vol/vol) [22]. For lipid
analyses, aliquots of the lipid extracts were dried and the
lipids were dissolved using a 1:1-mixture of chloroform
and Triton X-100. Subsequently, concentrations of tri-
glycerides in samples were determined by an enzymatic
reagent kit (Fluitest TG, obtained from Analyticon Bio-
technologies AG, Lichtenfels, Germany) [23].
Carnitine analysis
Concentrations of free carnitine and acetyl carnitine in
plasma and tissues were determined by tandem mass
spectrometry with deuterated carnitine-d3 (Cambridge
Isotype Laboratories, Andover, MA, USA) as internal
standard as described recently in detail [24]. Total carni-
tine was calculated as the sum of free carnitine and
acetyl carnitine.
RNA isolation and Quantitative real-time RT-PCR (qPCR)
Total RNA was isolated from 20 mg of each liver - and
samples of M. quadriceps femoris using Trizol reagent
(Invitrogen, Karlsruhe, Germany) according to the man-
ufacturer’s protocol. Genomic DNA was removed from
total RNA isolated with on-column DNase I digestion
using RNeasy Mini Kit columns (Qiagen, Germany).
After RNA isolation, concentration and purity were esti-
mated from the optical density at 260 and 280 nm, re-
spectively, using an Infinite 200M microplate reader and
a NanoQuant Plate (both from Tecan, Männedorf,
Switzerland). The integrity of the total RNA was checked
by 1% agarose gel electrophoresis. RNA was judged as
suitable only if the samples exhibited intact bands corre-
sponding to the 18S and 28S ribosomal RNA subunits.
Isolated RNA was preserved at −80°C until use. RelativemRNA concentrations were determined using real-time
detection RT-PCR (qPCR) carried out on a Rotorgene
2000 system (Corbett Research, Mortlake, Australia). For
this end, cDNA was synthesized from 1.2 μg of total
RNA using 100 pmol dT18 primer (Eurofins MWG Op-
eron, Ebersberg, Germany), 1.25 μL 10 mmol/L dNTP
mix (GeneCraft, Lüdinghausen, Germany), 5 μl buffer
(Fermentas, St. Leon-Rot, Deutschland), and 60 units
M-MuLV Reverse Transcriptase (MBI Fermentas, St.
Leon-Rot, Germany) at 42°C for 60 min, and a final in-
activating step at 70°C for 10 min in Biometra Thermal
Cycler (Whatman BiometraW, Göttingen, Germany).
Subsequently, cDNA was stored in aliquots at −20°C.
For the standard curve a cDNA pool of all samples each
from liver and muscle was made. qPCR was performed
using 2 μL cDNA combined with 18 μL of a mixture
composed of 10 μl KAPA SYBR FAST qPCR Universal
Mastermix (Peqlab, Erlangen, Germany), 0.4 μL each of
10 μM forward and reverse primers and 7.2 μL DNase/
RNase free water in 0.1 mL tubes (Ltf Labortechnik,
Wasserburg, Germany). Gene-specific primer pairs
obtained from Eurofins MWG Operon were designed
using PRIMER3 and BLAST. Characteristics of primer
pairs are listed in Table 1. Wherever possible, matching
primers were designed to be located in different exons.
The amplification of single product of the expected size
was approved using 2% agarose gel electrophoresis
stained with GelRed™ nucleic acid gel stain (Biotium
Inc., Hayward, CA). To minimize the influence of
confounding variables and to improve the accuracy of
the quantification process, expression values of target
genes were normalized using the GeNorm normalization
factor. GeNorm is a freely available software based on
the excel platform and allows the selection of the most
eligible reference gene by using the geometric mean of
the expression of the candidate cDNA [25]. In order to
calculate the normalization factor, all Ct values were
transformed into relative quantification data by using
the 2-△Ct equation [26], and the highest relative quan-
tities for each gene were set to 1, as described previously
[15]. From these values the GeNorm normalization fac-
tor was calculated from the three reference genes show-
ing the lowest M values (liver: CANX, YWHAZ, MDH1;
muscle: CANX, YWHAZ, TOP1; Table 1), indicating the
most stable expression out of the six tested candidate
reference genes. Candidate reference genes are usually
chosen from housekeeping genes which are not regulated
or influenced by the experimental procedure. Six house-
keeping genes were selected from commonly used refe-
rence genes listed by the company primerdesign (URL:
http://www.primerdesign.co.uk/genorm_all_species.html).
After normalization of gene expression data using the
calculated GeNorm normalization factor, means and SD
were calculated from normalized expression data for
Table 1 Characteristics and performance data of the primers used for reference gene-stability measure M and qPCR
Gene Forward primer (50→30) Product size (bp) NCBI GenBank Slope R21 Efficiency2 M
Reverse primer (50→30) Liver Muscle Liver Muscle Liver Muscle Liver Muscle
Reference genes
ATP5B GCACCGTCAGAACTATTGCT 203 NM_134364.1 −0.31 −0.34 0.99 0.99 2.04 2.00 0.069 0.149
GAATTCAGGAGCCTCAGCAT
CANX CCAGATGCAGATCTGAAGAC 175 NM_172008.2 −0.32 −0.32 0.99 0.99 2.10 1.98 0.065 0.082
CTGGGTCCTCAATTTCACGT
MDH1 CAGACAAAGAAGAGGTTGCC 206 NM_033235.1 −0.32 −0.32 0.99 0.99 2.07 2.10 0.054 0.111
CGTCAGGCAGTTTGTATTGG
RPL13 CTTAAATTGGCCACGCAGCT 198 NM_031101.1 −0.23 −0.30 0.88 0.99 1.70 2.01 0.072 0.105
CTTCTCAACGTCTTGCTCTG
TOP1 GAAGAACGCTATCCAGAAGG 137 NM_022615.1 −0.29 −0.30 0.99 0.99 1.95 2.20 0.066 0.088
GCTTTGGGACTCAGCTTCAT
YWHAZ GACGGAAGGTGCTGAGAAA 198 NM_013011.3 −0.30 −0.30 0.98 0.99 2.02 2.08 0.057 0.082
GCAGCAACCTCAGCCAAGT
Target genes
IGF-1 CCCGGGACGTACCAAAATGAGCG 354 NM_001082477.2 −0.29 0.99 1.97
ATGTCAGTGTGGCGCTGGGC
FBXO32 GACTGGACTTCTCGACTGCC 242 NM_133521.1 −0.29 0.98 1.94
GACTTGCCGACTCTCTGGAC
TRIM63 AAGGCAGCCACCCGATGTGC 110 NM_080903.1 −0.31 0.99 2.02
GCCTGGTGAGCCCCGAACAC
1Coefficient of determination of the standard curve.
2The efficiency was determined by [10-slope].
ATP5B: ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide; CANX: calnexin; MDH1: soluble malate dehydrogenase; RPL13: ribosomal
protein L13; TOP1: topoisomerase (DNA) I; YWHAZ: tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide;
IGF-1: insulin-like growth factor 1; FBXO32: F-box protein 32; TRIM63: tripartite motif containing 63.
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control group was set to 1 and means and SD of the
treatment group were scaled proportionally. Data on
qPCR performance for each gene measured in liver and
muscle are shown in Table 1.
Immunoblot analysis
Tissue homogenates and subsequent protein determin-
ation in samples of M. quadriceps femoris were carried
out as described above. For immunoblot analysis, 30 μg
protein from each homogenate were separated on
12.5% SDS-PAGE and electrotransferred to a nitrocellu-
lose membrane (Pall Corporation, Pensacola, FL, USA).
To detect ubiquitin-protein conjugates 30 μg protein
from each homogenate were separated on 7.5% SDS-
PAGE. Loading of equal amounts of protein in each
line was verified by Ponceau S (Carl Roth, Karlsruhe,
Germany) staining. After incubation the membranes
overnight at 4°C in blocking solution (5% nonfat dried
milk powder), membranes were incubated with primary
antibodies against MuRF1 (polyclonal anti-MuRF1 anti-
body; Santa Cruz Biotechnology, Inc., Santa Cruz, Ca,USA), atrogin-1/Fbx32 (polyclonal anti-Fbx32 antibody;
Abcam, Cambridge, UK), ubiquitin (polyclonal anti-
ubiquitin antibody, Abcam, Cambridge, UK), Akt1 (poly-
clonal anti-Akt1 antibody; Cell Signaling Technology,
Boston, MA, USA), hosphor-Akt1 (at Ser473) (monoclo-
nal anti-pAkt1 antibody; Cell Signaling Technology, Boston,
MA, USA), FoxO1 (polyclonal anti-FoxO1 antibody;
Cell Signaling Technology, Boston, MA, USA), hosphor-
FoxO1 (at Ser256) (polyclonal anti-pFoxO1 antibody; Cell
Signaling Technology, Boston, MA, USA), mTOR (poly-
clonal anti-mTOR antibody; Cell Signaling Technology,
Boston, MA, USA), hosphor-mTOR (at Ser2481) (poly-
clonal anti-pmTOR antibody; Cell Signaling Technology,
Boston, MA, USA), hosphor-mTOR (at Ser2448) (poly-
clonal anti-pmTOR antibody; Cell Signaling Technol-
ogy, Boston, MA, USA) and α-Tubulin (polyclonal
anti-α-Tubulin antibody; Cell Signaling Technology,
Boston, MA, USA) and GAPDH (monoclonal anti-
GAPDH antibody; Abcam, Cambridge, UK) as reference
proteins to control for adequate normalization. The
membranes were washed, and then incubated with a
horseradish peroxidase conjugated secondary monoclonal
Table 2 Growth performance data, skeletal muscle weights,
muscle protein concentrations and muscle triglyceride
concentrations of rats fed diets without (Control) or with
supplemented carnitine (Carnitine)
Control Carnitine
Food intake (g/d) 26.3 ± 2.4 25.8 ± 2.1
Final body weight (g) 353 ± 31 334 ± 28
Feed conversion ratio (g feed/g BWG) 3.11 ± 0.54 3.20 ± 0.44
Muscle weights (g)
M. quadriceps femoris 1.08 ± 0.08 1.09 ± 0.07
M. EDL 0.51 ± 0.07 0.52 ± 0.09
M. gastrocnemius 1.86 ± 0.09 1.90 ± 0.08
M. soleus 0.15 ± 0.01 0.15 ± 0.02
Muscle protein concentration (mg/g wet tissue)
M. quadriceps femoris 108 ± 10 111± 11
M. EDL 102 ± 9 113± 10*
M. gastrocnemius 108 ± 15 111± 15
Muscle triglyceride concentration (mg/g wet tissue)
M. quadriceps femoris 1.42 ± 0.66 1.28 ± 0.46
M. EDL 1.06 ± 0.43 0.84 ± 0.17
M. gastrocnemius 1.29 ± 0.32 1.24 ± 0.33
Values are means ± SD (n = 12/group). * indicates a significant difference to the
control group (P < 0.05). BWG: body weight gain; M: musculus; EDL: extensor
digitorum longus.
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Germany) for hosphor-Akt1, polyclonal anti-rabbit-
IgG antibody (Sigma-Aldrich, Steinheim, Germany)
for atrogin-1/Fbx32, ubiquitin, Akt1, FoxO1, hosphor-
FoxO1, α-Tubulin, mTOR, phosphor-mTOR (Ser2448
and Ser2481) and polyclonal anti-goat-IgG antibody
(Santa Cruz Biotechnology, Santa Cruz, Ca, USA) for
MuRF1 at RT. Afterwards blots were developed using
ECL Plus or ECL Advanced (both GE Healthcare,
Munich, Germany). The signal intensities of specific
bands were detected with a Bio-Imaging system (Syngene,
Cambridge, UK) and quantified using Syngene GeneTools
software (nonlinear dynamics).
Determination of IGF-1
The concentration of IGF-1 in plasma of rats was deter-
mined using a commercial enzymelinked immunosorbent
assay (ELISA) kit (R&D Systems, Wiesbaden-Nordenstadt,
Germany).
Statistical analysis
Values presented in the text are means ± SD. Data were
analyzed by one factorial analysis of variance with dietary
carnitine concentration as factor using the Minitab statis-
tical software (Release 13, Minitab Inc., State College, PA,
USA). Statistical significance of differences of the mean
values of the two groups of rats was evaluated using Stu-
dent’s t test. Means were considered significantly different
at P < 0.05.
Results
Growth performance and skeletal muscle weights
Food intake, final body weights after four weeks, feed
conversion ratio (g feed/g body weight gain) and weights
of M. quadriceps femoris, M. extensor digitorum longus,
M. gastrocnemius and M. soleus were not different be-
tween both groups of rats (P > 0.05; Table 2).
Concentrations of proteins and triglycerides in muscles
In order to investigate whether carnitine supplementa-
tion could have an influence on the composition of
muscles, concentrations of protein and triglycerides in
M. quadriceps femoris, M. extensor digitorum longus
and M. gastrocnemius were determined. Protein con-
centrations in M. quadriceps femoris and M. gastrocnemius
did not differ between the two groups of rats, while rats
fed the diet supplemented with carnitine had a higher pro-
tein concentration in M. extensor digitorum longus than
rats of the control group (P < 0.05, Table 2). Concentra-
tions of triglycerides did not differ in any muscle between
the two groups of rats (P > 0.05; Table 2). Total masses of
protein in the three muscles as well as the ratios between
protein and triglycerides in the three muscles considered
did not differ between the two groups (data not shown).Carnitine concentrations in plasma, liver and skeletal
muscle
Rats fed the diet supplemented with carnitine had higher
concentrations of free carnitine, acetyl carnitine and
total carnitine in plasma, liver and muscle than control
rats (P < 0.05; Table 3).
Relative mRNA and protein concentrations of FBXO32
(encoding atrogin-1) and TRIM63 (encoding MuRF1) in
skeletal muscle
Rats fed the diet supplemented with carnitine had lower
relative mRNA and protein concentrations of tripartite
motif containing 63 (TRIM63; encoding MuRF1) in the
muscle than control rats (P < 0.05; Figure 1A-C). Rela-
tive mRNA- and protein concentrations of F-box protein
32 (FBXO32; encoding atrogin-1) in muscle were slightly
lower in rats fed the diet supplemented with carnitine
than in control rats; the differences were however not
statistically significant (Figure 1A-C).
Relative protein concentrations of ubiquitinated protein
conjugates
In line with the decreased expression of MuRF1, rats
fed the diet supplemented with carnitine had lower
amounts of ubiquitinated proteins with different molecular
masses in skeletal muscle than control rats (P < 0.05;
Figure 2).
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Figure 1 Relative mRNA abundance of FBXO32 and TRIM63
(A) and relative protein concentrations of atrogin-1 and MuRF1
(B,C) in M. quadriceps femoris of rats fed either a control diet
(0 mg carnitine/kg diet; Control) or a diet supplemented with
1250 mg carnitine/kg diet (Carnitine). (A) Bars are means ± SD
(n = 12/group). The normalized expression ratio in the control
group is set to 1.0. * indicates a significant difference to the control
group (P < 0.05). (B) Representative immunoblots specific to
atrogin-1, MuRF1 and GAPDH as internal control are shown for one
animal per group; immunoblots for the other animals revealed
similar results. (C) Bars represent data from densitometric analysis
and represent means ± SD (n = 6/group); bars are expressed
relative to the protein level of the control group (= 1.00). * indicates a
significant difference to the control group (P < 0.05).
Table 3 Concentrations of free carnitine, acetyl carnitine
and total carnitine in plasma, liver and muscle of rats fed
diets without (Control) or with supplemented carnitine
(Carnitine)
Control Carnitine
Plasma (μmol/l)
Free carnitine 36 ± 5 91 ± 7*
Acetyl carnitine 16 ± 3 42 ± 6*
Total carnitine 52 ± 7 133 ± 10*
Liver (nmol/g dry matter)
Free carnitine 595 ± 70 1142 ± 158*
Acetyl carnitine 23 ± 13 74 ± 25*
Total carnitine 618 ± 72 1216 ± 142*
Muscle (nmol/g dry matter)
Free carnitine 2153 ± 321 3465 ± 420*
Acetyl carnitine 1246 ± 198 2571 ± 266*
Total carnitine 3399 ± 452 6036 ± 450*
Values are means ± SD (n = 12/group). * indicates a significant difference to the
control group (P < 0.05).
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concentration of IGF-1
Rats fed the diet supplemented with carnitine had higher
relative mRNA concentrations of IGF-1 in the liver and
a higher concentration of IGF-1 in plasma than control
rats (P < 0.05; Figure 3A and B).
Relative protein concentrations of total and
phosphorylated Akt1, FoxO1 and mTOR
Rats fed the diet supplemented with carnitine had a re-
duced concentration of total Akt1, an increased concen-
tration of phospho-Akt1 concentration and an increased
ratio of phospho-Akt1 to total Akt1 in skeletal muscle
(P < 0.05; Figure 4A and B), indicative of an activation of
IGF-1/PI3K/Akt signalling pathway. The protein con-
centration of total and phosphorylated FoxO1 in skeletal
muscle was not different between both groups of rats
(Figure 4A and B). However, the ratio of phospho-
FoxO1 to total FoxO1 was lower in skeletal muscle of
rats fed the diet supplemented with carnitine than in
control rats, indicating that carnitine stimulates phos-
phorylation and thereby inactivation of FoxO1 (P < 0.05;
Figure 4A and B). As activation of IGF-1/PI3K/Akt sig-
nalling pathway is known to stimulate protein synthesis
by activation of the mammalian target of rapamycin
(mTOR), we also determined protein levels of total and
phospho-mTOR (at Ser2448 and Ser2481) and calculated
the phospho-mTOR and total mTOR ratio. The protein
concentration of total mTOR in skeletal muscle was re-
duced in rats fed the diet supplemented with carnitine
whereas the concentrations of phospho-mTOR (Ser2448,
Ser2481) were markedly increased compared to control rats(P < 0.05; Figure 5A and B). The ratios of phospho-mTOR
(Ser2448 and Ser2481) to total mTOR tended to be higher in
skeletal muscle of rats fed the diet supplemented with car-
nitine compared to control rats (P < 0.1; Figure 5A and B).
Discussion
Recent studies have shown that supplementation of car-
nitine suppresses the expression of genes of the UPS in
skeletal muscle and reduces loss of muscle mass under
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Figure 2 Relative protein levels of ubiquitin-protein conjugates in M. quadriceps femoris of rats fed either a control diet (0 mg carnitine/
kg diet; Control) or a diet supplemented with 1250 mg carnitine/kg diet (Carnitine). (A) A representative immunoblot specific to ubiquitin is
shown for three animals per group; immunoblots for the other animals revealed similar results. Reversible staining of nitrocellulose membranes
with Ponceau S revealed equal loading of protein. (B) Bars represent data from densitometric analysis and represent means ± SD (n = 6/group);
bars are expressed relative to the protein level of the control group (= 1.00). * indicates a significant difference to the control group (P < 0.05).
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http://www.nutritionandmetabolism.com/content/10/1/28catabolic conditions [15,16]. The present study investi-
gated the hypothesis that this phenomenon could be me-
diated by an activation of the IGF-1/PI3K/Akt signalling
pathway. To investigate this hypothesis, we performed a
feeding experiment with rats fed either a control diet
with a low native carnitine concentration or the control
diet supplemented with 1250 mg carnitine per kg, a dose
which – according to the recent experiments [15,16] -
might be effective to induce the expected effect on genesof the UPS. The finding that supplementation of carni-
tine does not influence body weight gains of the growing
rats but markedly increases plasma and tissue carnitine
concentrations agrees with several other studies
[15,27-29]. In this study, we found that supplementation
of carnitine suppresses the expression of MuRF1 in skel-
etal muscle but does not significantly reduce the expres-
sion of atrogin-1. This finding agrees with the recent
study of Busquets et al. [16] showing that carnitine
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Figure 3 (A) Relative mRNA abundance of IGF-1 in liver of rats
fed either a control diet (0 mg carnitine/kg diet; Control) or a
diet supplemented with 1250 mg carnitine/kg diet (Carnitine).
Bars are means ± SD (n = 12/group). The normalized expression
ratio in the control group is set to 1.0. * indicates a significant
difference to the control group (P < 0.05). (B) Concentration of IGF-1
(ng/ml) in plasma of rats fed either a control diet (0 mg carnitine/kg
diet; Control) or a diet supplemented with 1250 mg carnitine/kg
diet (Carnitine). Bars represent mean ± SD (n = 12/group). * indicates
a significant difference to the control group (P < 0.05).
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http://www.nutritionandmetabolism.com/content/10/1/28lowers the expression of MuRF1 but not that of atrogin-
1 in skeletal muscle of rats suffering from cancer cach-
exia. In contrast to these findings in rats, supplementa-
tion of carnitine in pigs lowered the expression of both
of the E3 ligases [15], indicating that the effect of carni-
tine on the expression of E3 ligases in skeletal muscle
might be species-specific. In agreement with a down-
regulation of MuRF1, we observed reduced concentra-
tions of ubiquitin-protein conjugates in skeletal muscle
of rats fed a diet supplemented with carnitine. For tech-
nical reasons, we did not examine muscle protein break-
down in this study. Ubiquitination is a rate-limiting step
in the proteolysis of muscle proteins by the UPS [30].
Therefore it seems likely that protein degradation in
muscle was also reduced by carnitine in rat skeletal
muscle. It has been shown that myofibrillar proteins, like
myosin light chain proteins are the main targets of
MuRF1 for ubiquitination [31]. Thus, carnitine might
suppress particularly the degradation of myofibrillar pro-
teins, which under physiological conditions comprise
around 60% of total muscle proteins [31]. In contrast to
MuRF1, atrogin-1 tags primarily proteins for degradation
which are important for controlling protein synthesis
and myoblast differentiation, like myogenic factor MyoD,
myogenin and the eukaryotic initiation factor of protein
synthesis eIF3-f [32-35].
The present study confirms recent studies in humans,
pigs, rats and chickens in showing that supplementation
of carnitine increases plasma IGF-1 concentrations
[17-19,36-38]. IGF-1 is an important regulator of the ac-
tivity of the UPS. Several studies have shown that IGF-1
inhibits muscle protein degradation [39-42]. This effect
is induced by an activation of the PI3/Akt signalling
pathway which in turn inhibits the expression of E3 li-
gases due to an inactivation of FoxOs [14,43]. In the
present study, we indeed observed an activation of the
PI3/Akt signalling pathway and an inactivation of FoxOs
in the skeletal muscle of rats fed a diet supplemented
with carnitine. These observations suggest that down-
regulation of MuRF1 in muscle of rats fed a diet
supplemented with carnitine was indeed mediated by
increased plasma concentrations of IGF-1 and an acti-
vation of the PI3/Akt signalling pathway. It is known
that IGF-1 induces muscle hypertrophy not only by
AB
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Figure 4 Relative protein concentrations of total and phosphorylated Akt1 and FoxO1 and calculated phospho-Akt1/total Akt1 and
phospho-FoxO1/total FoxO1 ratios in M. quadriceps femoris of rats fed either a control diet (0 mg carnitine/kg diet; Control) or a diet
supplemented with 1250 mg carnitine/kg diet (Carnitine). (A) Representative immunoblots specific to total Akt1, phospho-Akt1, total FoxO1,
phospho-FoxO1 and GAPDH as internal control are shown for one animal per group; immunoblots for the other animals revealed similar results.
(B) Bars represent data from densitometric analysis and represent means ± SD (n = 6/group); bars are expressed relative to the protein level of
the control group (= 1.00). * indicates a significant difference to the control group (P < 0.05).
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http://www.nutritionandmetabolism.com/content/10/1/28suppression of protein degradation but also by an in-
crease in protein synthesis due to activation of the
downstream mTOR-pathway [44]. According with this
function of IGF-1, we observed an increase in phos-
phorylated mTOR at Ser2448 and Ser2481 in skeletal
muscle of rats fed the diet supplemented with carnitine
compared to control rats. Although we did not study
protein synthesis in muscle, this finding suggests that
carnitine could also promote protein synthesis in skel-
etal muscle.
Down-regulation of E3-ligases in muscle and an ac-
tivation of the mTOR-pathway are expected to in-
crease skeletal muscle weights and to improve whole
body N-balance. Indeed, in the study of Busquets
et al. [16], suppression of the UPS by carnitine led toa reduction of muscle wasting and to an improvement
of the whole body N-balance in rats suffering from can-
cer cachexia. Unexpectedly, although carnitine exerted
clear effects on UPS and mTOR-pathway via an in-
crease of plasma IGF-1 concentrations, no changes in
body weights and muscle weights of the rats were ob-
served in the present study. This finding agrees with a
recent study in fast growing pigs, in which carnitine
supplementation did also not improve weight gains
and the feed conversion ratio in spite of a clear
down-regulation of E3-ligases in liver and skeletal
muscle [15]. In pigs, it has been however observed
that supplementation of carnitine enhances protein
accretion at the expense of fat deposition [45,46]. In
order to investigate whether carnitine could have
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Figure 5 Relative protein concentrations of total and phosphorylated mTOR at Ser2448 and Ser2481 and calculated phospho-mTOR
(Ser2448)/total mTOR and phosphor-mTOR (Ser2481)/total mTOR ratios in M. quadriceps femoris of rats fed either a control diet (0 mg
carnitine/kg diet; Control) or a diet supplemented with 1250 mg carnitine/kg diet (Carnitine). (A) Representative immunoblots specific to
total mTOR, phosphor-mTOR (Ser2448), phosphor-mTOR (Ser2481) and α-Tubulin as internal control are shown for one animal per group; immunoblots for
the other animals revealed similar results. (B) Bars represent data from densitometric analysis and represent means ± SD (n = 6/group); bars are
expressed relative to the protein level of the control group (= 1.00). * indicates a significant difference to the control group (P < 0.05).
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http://www.nutritionandmetabolism.com/content/10/1/28changed the composition of muscle, we determined
protein and triglyceride concentrations in skeletal mus-
cles. We did however not find differences in the pro-
tein/triglyceride ratios, suggesting that carnitine did
also not change composition of skeletal muscle in
healthy, growing rats. In growing animals, the rate of
protein synthesis strongly exceeds protein degradation
[47]. What we suspect is that under the condition of fast
growth, the effect of suppression of the UPS by carnitineon muscle protein balance might be superimposed by the
high rate of protein synthesis. Probably, the suppression of
the UPS by carnitine with respect to muscle protein
degradation might be more pronounced and more rele-
vant under condition of negative N balance, chronic dis-
eases and denervation or under unloading conditions.
Under such conditions, the UPS is strongly up-regulated
leading to muscle atrophy and a reduction of the mass of
skeletal muscles [7,48,49]. The finding of Busquets et al.
Keller et al. Nutrition & Metabolism 2013, 10:28 Page 11 of 12
http://www.nutritionandmetabolism.com/content/10/1/28[16] that carnitine reduces muscle wasting in rats suf-
fering from cancer cachexia indeed suggests that carni-
tine exerts beneficial effects on muscle mass particularly
under conditions associated with an increased activity
of the UPS.
In conclusion, the present study shows that supple-
mentation of carnitine to rats leads to a down-regulation
of MuRF1 and a decrease in the content of ubiquitinated
proteins in skeletal muscle, indicating that degradation
of myofibrillar proteins by the UPS was reduced. The
study moreover suggest that this effect could be at least
in part due to increased plasma levels of IGF-1 which in
turn led to an activation of the IGF-1/PI3K/Akt signal-
ling pathway and to an inactivation of FoxO1, the tran-
scriptional regulator of MuRF1.
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